Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction

Who May Qualify: - 1\. Male and female aged ≥19 years and ≤ 80 years - 2\. A clinical diagnosis of acute myocardial infarction within 4 weeks from randomization - 3\. Successful percutaneous coronary intervention to the target lesion (TIMI flow grade 3 and residual stenosis \<30% at the target lesion) with a drug-eluting stent and/or drug-eluting balloon - 4\. Agreement to give written willing to sign a consent form. Who Should NOT Join This Trial: 1. Patients with uncontrolled heart failure (Killip class ≥ grade 2, or left ventricular ejection fraction \<20%) 2. Patients with uncontrolled chest pain due to ischemia 3. Patients with uncontrolled arrythmia 4. Active malignancy, or incompletely treated malignancy 5. Active infectious disease 6. Uncontrolled hematologic disease, including coagulopathy or bleeding diathesis 7. Presence of non-cardiac comorbidity with life expectancy ≤1 year from randomization 8. Females with childbearing potential or breast-feeding 9. Refusal to give written willing to sign a consent form 10. Other conditions that may result in protocol non-compliance by the committees Always talk to your doctor about whether this trial is right for you.